BACKGROUND: The role of mycoplasmas on the development and sequelae of pelvic inflammatory disease remains controversial. The objective of the present study is to correlate directly the presence of Mycoplasmateceae through polimerase chain reaction (PCR) determinations in cervix and Fallopian tubes of infertile patients with tubo-peritoneal factor diagnosed through laparoscopy. METHODS: Thirty patients with tubo-peritoneal infertility and 30 normal fertile patients were included in the study; cervical samples and tubal flushings were obtained during laparoscopy. PCR determinations for the detection of genetic material of Mycoplasma genitalium, Mycoplasma hominis, Ureaplasma urealiticum, Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis in cervix and tubal flushings were performed. RESULTS: No Mycoplasmataceae species as "only" microorganisms were found in tubal flushings of tubo-peritoneal infertility patients, whereas three (10%) fertile patients with normal tubes were positive for mycoplasma presence. This difference was not significant (p = 0.237). Among the 30 patients suffering from tubal infertility diagnosed through laparoscopy, Mycoplasmatecae species were not detected in the Fallopian tubes by PCR determinations, while in normal tubes from fertile patients these and other microorganisms could be found without distorting tubal anatomy. CONCLUSION: Mycoplasmateceae species were not detected in Fallopian tubes of women with tubo-peritoneal infertility.

In the present study, we investigated whether cellular damage, as demonstrated by lactate dehydrogenase (LDH) release in the human fallopian tube (FT) infected by Neisseria gonorrhoeae (Ngo), correlated with high levels of nitric oxide synthase (NOS) mRNA and enzyme activity. Infection with Ngo induced a significant increase (~35-fold) in mRNA transcripts of the inducible isoform of NOS. Paradoxically, a reduction in NOS enzyme activity was observed in infected cultures, suggesting that gonococcal infection possibly influences translation of iNOS mRNA to the enzyme. In addition, treatment with the NOS inhibitor TRIM did not prevent gonococcal-induced cellular damage. In contrast, the addition of the inhibitor L-NAME induced a 40% reduction in LDH release, which correlated with a ~50% reduction in gonococcal numbers. Moreover, treatment of normal FT explants with an exogenous NO donor, SNAP, did not induce significant cellular damage. Taken together, our data suggest that NO does not contribute to cellular damage during infection of the human FT with Neisseria gonorrhoeae.

We present the clinical experience with the use of metformyn (1.7 g per day) for four months in eleven patients with PCO associated with insulin resistance. We determinate the clinical effects, biochemical and hormonal changes during four month of therapy. Five of the patients, who wanted to get pregnant, continued receiving the drug for a year. We evaluated the clinical feelings menstrual history, hyrsutism and the levels of serum gonadotrophin, sex hormone-binding globulin (SHBG) basal insulin and postcharge glucose, lipid profile and ovarian volume. Seven of the eleven women (63.3%) start again the menstrual cycle. Three patients became pregnant between the fifth and seventh month (60%), one of them have an abortion at eight-week. We didn't find changes in hirsutism, corporal mass and arterial pressure. The result was a significat disminution in plasmatic levels of basal insulin and post overcharge, of free testosterone and one increase of the SHBG. No changes in gonadotrophins, DHEAS, lipid profile levels and the average ovarian volume were seen. The drug have a good tolerance and we consider it a good and useful alternative in patient with over, weight and with PCO, menstrual changes and infertility, associated with hiperinsulinism and insulin resistance

Se presenta la experiencia clínica del uso de metformina (1,7 g día), por 4 meses, en 11 pacientes con (SOP) asociado a resistencia insulínica. Se determinaron los efectos clínicos, bioquímicos y hormonales luego de 4 meses de terapia. Cinco de las pacientes que deseaban embarazo, continuaron recibiendo la droga, hasta por un año. Se evaluó durante el tratamiento los síntomas clínicos, historia menstrual, hirsutismo; y los niveles séricos de gonadotrofinas, andrógenos, globulina ligante sexual, insulina basal y postsobrecarga de glucosa, perfil lipídico y volumen ovárico. Siete de 11 mujeres (63,3%) restablecieron la ciclicidad menstrual. Tres pacientes lograron embarazo entre el 5º y 7º mes de tratamiento (60%) una de ellas presentó un aborto a las 8 semanas. No se observaron cambios en el hirsutismo índice de masa corporal y presión arterial. Hubo una disminución significativa de los niveles plasmáticos de insulina tanto basal como postsobrecarga; de la testosterona libre y un incremento de SHBG. No hubo cambios en los niveles de gonadotrofinas, dehidroepiandosterona sulfato (DHEAS) perfil lipídico ni del volumen ovárico promedio. La droga fue bien tolerada, y la consideramos como una alternativa útil en pacientes obesas con (SOP) con alteraciones menstruales y o infertilidad, asociada a hiperinsulinemia y resistencia insulínica